

Datasheet: PIP006

BATCH NUMBER 163732

Description:	NATIVE DENGUE VIRUS TYPE 2
Name:	DENGUE VIRUS TYPE 2
Format:	Inactivated Pathogen
Product Type:	Antigen
Quantity:	1 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Viral
Product Form	Inactivated, highly purified preparation of Dengue virus type 2 particles - liquid.
Preparation	Dengue virus type 2 strain 16681 cultured in Vero cells. Dengue virus particles are concentrated from tissue culture supernatant by precipitation and ultracentrifugation. Antigen is purified by sucrose density gradient centrifugation. Virus particles are separated from the sucrose containing buffer by ultracentrifugation before resuspension in Medium 199. The antigen preparation is inactivated by room temperature incubation with formaldehyde. The formaldehyde is neutralised by the addition of sodium bisulphite.
Buffer Solution	Medium 199
Preservative Stabilisers	None present
Approx. Protein Concentrations	Current, batch-specific concentration 0.9 mg/ml
Product Information	Native Dengue Virus Type 2 is a preparation of viral particles concentrated from tissue

culture supernatant. Dengue Virus Type 2 is one of four antigenically distinct yet closely related viral serotypes belonging to the family Flaviviridae known to cause Dengue fever in humans. Dengue infection is a major cause of morbidity in tropical and subtropical regions. It is a mosquito borne viral infection that may be asymptomatic or may cause undifferentiated fever, dengue fever, dengue haemorrhagic fever or dengue shock syndrome. Currently, there is no vaccine or effective antiviral drugs to treat the infection.

Activity	Antigenic activity is 210 % of internal reference standard.
-----------------	---

References	1. Suzuki, K. & Iwamoto, H. (0) Immunochromatography analysis device for detecting zika virus. US Patent: US20190162727A1
-------------------	---

Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.
----------------	---

Guarantee	Guaranteed until date of expiry. Please see product label.
------------------	--

Health And Safety Information	Material Safety Datasheet documentation #10286 available at: https://www.bio-rad-antibodies.com/SDS/PIP006 10286 This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.
--------------------------------------	---

Regulatory	For research purposes only
-------------------	----------------------------

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M412304:221110'

Printed on 14 Nov 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)